Loading...
XPAR
AELIS
Market cap19mUSD
May 05, Last price  
1.26EUR
1D
1.61%
1Q
-55.00%
IPO
-89.50%
Name

Aelis Farma SA

Chart & Performance

D1W1MN
P/E
—
P/S
1.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.10%
Rev. gr., 5y
195.83%
Revenues
9m
+137.70%
85,47239,9588,8511,137,0009,075,0003,809,0009,054,000
Net income
-5m
L-64.46%
-1,002,795-2,731,000-3,247,000-2,086,000574,000-14,288,000-5,078,000
CFO
-13m
L-3.56%
0-3,548,000-2,888,000-2,478,00018,970,000-13,051,000-12,586,000

Profile

Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.
URL
https://www.aelisfarma.com/
IPO date
Feb 18, 2022
Employees
20
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
9,054
137.70%
3,809
-58.03%
Cost of revenue
14,007
15,462
Unusual Expense (Income)
NOPBT
(4,953)
(11,653)
NOPBT Margin
Operating Taxes
3
1,000
Tax Rate
NOPAT
(4,956)
(11,654)
Net income
(5,078)
-64.46%
(14,288)
-2,589.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
127
25,544
BB yield
-0.08%
-15.93%
Debt
Debt current
1,094
814
Long-term debt
3,958
3,017
Deferred revenue
584
Other long-term liabilities
102
58
Net debt
(15,178)
(30,780)
Cash flow
Cash from operating activities
(12,586)
(13,051)
CAPEX
(88)
(137)
Cash from investing activities
(88)
(86)
Cash from financing activities
(1,967)
22,097
FCF
(5,962)
(11,635)
Balance
Cash
20,230
34,396
Long term investments
215
Excess cash
19,777
34,421
Stockholders' equity
(10,065)
(12,462)
Invested Capital
27,408
36,050
ROIC
ROCE
EV
Common stock shares outstanding
12,899
11,840
Price
13.10
-3.25%
13.54
 
Market cap
168,974
5.40%
160,313
 
EV
153,796
129,533
EBITDA
(4,785)
(11,583)
EV/EBITDA
Interest
159
112
Interest/NOPBT